Pinc PeptideThe girly peptide research blog

KPV · Dose evidence · updated 8 October 2026

KPV dosage: what studies actually used

The short answer

FDA found no study that gave KPV to people by any route, and we found no trial of it, so there is no human dose to report34. The one product strength documented in FDA’s review is 0.1%, in a cream or gel for the skin that was nominated for pharmacy compounding, and FDA found no human data for that form either3. On 23 July 2026, FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, in favor of adding KPV to the list of substances pharmacies may compound with, against FDA’s own review, but the vote is only advisory56.

Not dosing advice. This page reports doses that studies and approved labels used, with their sources. It does not recommend a dose, and we do not give mixing, injection or unit-conversion instructions. Gray-market vials often do not contain what their label says. How we report doses.

Studies, animals and users: kept apart

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

None. Neither FDA nor our searches found a human study of KPV, so we know of no dose tested in people by any route, including the 0.1% topical cream and gel nominated to FDA and the injected, oral and nasal products sold online34.

In animal studies

As reported in the papers, in animals only. Mice with colitis: KPV at 100 micromolar in drinking water9. Mice with crystal-induced peritonitis: systemic KPV before the irritant10. Rabbits with fever: 0.5 to 2.0 mg into the brain and 2 to 200 mg by peripheral routes11. Rabbits with scraped corneas: drops of 1, 5 or 10 mg/ml, 30 microlitres, two drops four times a day for 4 days12. Mice with brain injury: 1 mg/kg into the abdomen 30 minutes after the injury13. These are animal doses. They are not human doses, and we do not convert them.

What users report Anecdotal · not validated · not a recommendation

One community protocol page lists 200 to 500 micrograms a day7, and a second community site gives the same daily range8. FDA found no human study of KPV, so none supports these figures3.

Half-life and how it is taken

Routes
  • Topical cream and gel (the form nominated to FDA; no human data found)
  • Injection under the skin (a common gray-market route; no human data found)
  • By mouth, as capsules (no human data found; mouse studies used drinking water or nanoparticles)
  • Nasal spray (no human data found)
  • Eye drops (one rabbit study)

The 0.1% cream and gel nominated to FDA

Wells Pharmacy Network nominated KPV for FDA’s list of bulk substances that pharmacies may compound with, in a filing that FDA’s public docket shows as received on 25 March 202113. It proposed a cream or gel at a strength of 0.1%, applied to the skin, for wound healing and inflammatory conditions such as psoriasis and eczema, and gave as its reason that no FDA-approved product was available3. The nomination cited nine references, and none of them studied KPV given to people3.

The nomination gave no information on the formulation of the cream or gel, so FDA could not judge how KPV’s limited solubility in water and its other properties would affect the finished product3. Its certificate of analysis also named one form of KPV in its title and another by its chemical formula, leaving unclear whether the free base or the acetate salt was meant3. Wells withdrew the nomination on 14 April 2026, in a filing that withdrew 12 peptide nominations at once, but FDA went on to review both forms on its own initiative23.

What FDA’s review found

In a review dated 12 May 2026, written for its compounding advisory committee, FDA proposed not adding KPV free base or KPV acetate to the list of bulk substances that pharmacies may compound with3. Among its findings:

  • No human data by any route: neither the nominator nor FDA identified any clinical study or human exposure data, so the safety risks of KPV in people are unknown3.
  • No studies of how KPV is absorbed or cleared, in people or in animals, and no toxicity studies of the standard kinds, from single-dose and repeat-dose studies to tests for genetic damage, effects on reproduction and cancer3.
  • Poor skin penetration: in a laboratory study on skin from human cadavers, KPV did not pass well through the skin, which FDA said could keep it out of the bloodstream but could also limit its usefulness as a skin treatment314.
  • No reports of harm: searches of FDA’s adverse event database through 3 December 2025, and of its complaint system for foods, supplements and cosmetics from 1 January 2004 to 3 December 2025, found no cases, and FDA found no case reports of KPV use in people3.
  • Not well characterized: names for KPV do not follow standard naming systems, and key quality-control information was missing, including any certificate of analysis for the free base3.
  • Other options exist: FDA noted that approved treatments are available for wounds and for inflammatory diseases3.

FDA also found websites promoting compounded KPV taken by mouth, by injection, on the skin and as a nasal spray, while the nomination covered only a 0.1% cream or gel3.

The July 2026 advisory vote

FDA announced the committee meeting in the Federal Register on 16 April 2026, and the committee took up KPV on 23 July 20266. For KPV free base and KPV acetate alike, it voted 8 to 6, with 1 abstention, in favor of adding them to the list, against the recommendation of FDA’s own scientific review team, according to two law-firm accounts515.

The vote is advisory: FDA has said it will announce any final decision through notice-and-comment rulemaking5. As of 7 October 2026, FDA’s meeting page listed no minutes or transcript, and its 503A category lists were still dated 14 May 2026, with KPV in none of the categories1617.

What KPV products were found to contain

As of 5 October 2026, the testing service Finnrick listed 17 tests of KPV products from 7 vendors, dated 29 March to 10 September 2026: 2 passed, 13 failed and 2 were incomplete, under a standard of at least 99.5% purity and content within 35% of the label1819.

Questions people ask

How much KPV should I take?

No dose of KPV is established, because FDA found no study that gave it to people by any route, and we found no trial of it34. The only strength in FDA’s review is the 0.1% cream or gel proposed for compounding, and FDA found no human data on it3. KPV is not an approved drug, and US pharmacies may not compound it31720.

What strength is KPV cream?

The nomination sent to FDA proposed a 0.1% cream or gel for the skin, for wound healing and inflammatory conditions such as psoriasis and eczema3. FDA found no study that tested that strength, or any other, in people3.

Can you take KPV orally?

FDA found no study that gave KPV to people by mouth3. Mice received it in drinking water or in nanoparticles taken by mouth, and those are animal doses, not human ones921.

Did FDA approve KPV for compounding?

No. FDA’s review of 12 May 2026 proposed not adding KPV to the list of substances pharmacies may compound with3. Its advisory committee voted 8 to 6, with 1 abstention, in favor on 23 July 2026, but FDA’s lists were still dated 14 May 2026 as of 7 October 2026, and FDA has said any final decision will come through notice-and-comment rulemaking5617.

Go deeper

Sources

  1. 1Nomination from Wells Pharmacy Network (FDA-2015-N-3534-0294) Regulations.gov (U.S. Food and Drug Administration docket FDA-2015-N-3534), 1 Apr 2021. regulations.gov
  2. 2Withdrawal from Wells Pharmacy Network (FDA-2015-N-3534-0484) Regulations.gov (U.S. Food and Drug Administration docket FDA-2015-N-3534), 14 Apr 2026. regulations.gov
  3. 3FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate), Pharmacy Compounding Advisory Committee briefing document U.S. Food and Drug Administration, 12 May 2026. fda.gov
  4. 4ClinicalTrials.gov search for ‘KPV’ (no registered study) ClinicalTrials.gov, accessed 5 Oct 2026. clinicaltrials.gov
  5. 5PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
  6. 6Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments (91 FR 20465) Federal Register (U.S. Food and Drug Administration), 16 Apr 2026. federalregister.gov
  7. 7KPV 10 mg vial: dosage protocol PeptideDosages.com, 20 Sep 2026. peptidedosages.com
  8. 8KPV (Alpha-MSH Fragment) Dosage, Safety & Stacks Peptide Initiative, 10 Aug 2026. peptideinitiative.com
  9. 9PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology, Jan 2008. pubmed.ncbi.nlm.nih.gov
  10. 10Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides Journal of Pharmacology and Experimental Therapeutics, Aug 2003. pubmed.ncbi.nlm.nih.gov
  11. 11Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit Peptides, 1984. pubmed.ncbi.nlm.nih.gov
  12. 12Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide Experimental Eye Research, Dec 2006. pubmed.ncbi.nlm.nih.gov
  13. 13Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice PLoS One, 2013. pubmed.ncbi.nlm.nih.gov
  14. 14Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin Journal of Pharmaceutical Sciences, Jul 2017. pubmed.ncbi.nlm.nih.gov
  15. 15Bulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, 27 Jul 2026. mcdermottlaw.com
  16. 16July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
  17. 17Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  18. 18KPV: safety testing results and vendor ratings Finnrick, 10 Sep 2026. finnrick.com
  19. 19Methodology Finnrick, accessed 5 Oct 2026. finnrick.com
  20. 20Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
  21. 21Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Molecular Therapy, 5 Jul 2017. pubmed.ncbi.nlm.nih.gov

Not medical advice. Talk to a licensed clinician before using any drug. Report an error.